Do GLP-1s work for menopause weight gain, and what's different for women?

The short answer

Evidence tier: 1 — large randomised trials, FDA labels and a long-running cohort study (SWAN); the hormone-therapy data are observational.

Yes, GLP-1 drugs work for weight gained around menopause. In tirzepatide's SURMOUNT-1 trial, peri- and postmenopausal women lost about 23% of body weight versus 3% on placebo, close to the 26% seen in premenopausal women.

Women also tend to lose more than men on these drugs. That pattern holds across the tirzepatide trials and in a semaglutide heart-failure programme.

What changes after menopause is the risk side. About a quarter of the weight lost on a GLP-1 is lean mass. Women are already losing muscle and bone in the menopause transition, and the Wegovy label reports more hip and pelvic fractures in women on the drug than on placebo.

The key points:

• Menopause speeds up fat gain and lean-mass loss, and moves fat toward the abdomen, even when the scale barely moves.
• Semaglutide and tirzepatide work at every reproductive stage in trial data.
• Women using menopausal hormone therapy (MHT) lost more weight on semaglutide in two Mayo Clinic analyses, but neither was randomised.
• Bone and muscle are the main concerns for women over 50 on these drugs.
• Peptides sold for "menopause belly" (AOD-9604, 5-amino-1MQ, tesamorelin) have no trials in menopausal women and no approval for weight loss.

Why does weight shift to the belly during menopause?

Evidence tier: 3 — prospective cohort studies with DXA and CT scans.

The best data come from SWAN (Study of Women's Health Across the Nation), which followed midlife women through the menopause transition. Its body-composition analysis found that at the start of the transition the rate of fat gain doubled and lean mass began to fall. Both changes continued until about two years after the final period, then levelled off.

Total weight did not speed up at all. Fat went up while muscle went down by a similar amount, so the scale can hide a real change in body composition.

Where the fat goes changes too:

• A four-year CT study found that only women who became postmenopausal had a significant rise in visceral (deep abdominal) fat. The same women burned less energy during sleep and burned less fat.
• A SWAN sub-study found that bioavailable testosterone predicted visceral fat more strongly than estradiol. As estrogen falls, the hormone balance shifts toward androgens, and that may favour central fat.

Visceral fat matters more than the number on the scale because it is linked to diabetes and heart disease.

Do GLP-1s work as well after menopause?

Evidence tier: 1–2 — post hoc analyses of large randomised trials.

Yes. A Lilly-funded analysis split women from SURMOUNT-1, -3 and -4 by reproductive stage. In SURMOUNT-1 at the 15 mg or maximum tolerated dose, average weight loss was 26% premenopausal, 23% perimenopausal and 23% postmenopausal, against 2–3% on placebo. Waist size fell by about 20 cm in every group. Results in SURMOUNT-3 and -4 were similar.

The small gap between pre- and postmenopausal women is real but modest, and both groups far outperformed placebo.

Do women lose more weight than men on GLP-1s?

Evidence tier: 2 — prespecified and post hoc sex analyses of randomised trials.

On average, yes:

• Tirzepatide: a post hoc analysis of all four SURMOUNT trials, presented at EASD 2024, reported weight loss of 11.5–27.6% in women versus 8.8–18.9% in men.
• Semaglutide: in the STEP-HFpEF heart-failure trials, semaglutide 2.4 mg reduced body weight by 9.6% in women versus 7.2% in men, while symptom benefits were the same for both sexes.

Nobody knows why yet. Possible reasons include differences in body size, drug exposure per kilogram and appetite signalling. FDA labels for both drugs say weight loss was seen regardless of sex.

Does hormone therapy boost GLP-1 weight loss?

Evidence tier: 3 — retrospective cohort studies, one of them presented only as a conference abstract.

The first signal came from Mayo Clinic. Hurtado and colleagues reviewed records of 106 postmenopausal women on semaglutide. The 16 women using MHT lost 16% of body weight at 12 months, compared with 12% in the 90 not using it. The difference held after adjusting for confounders.

That study was small. A much larger Mayo-led analysis presented at The Menopause Society 2026 meeting matched about 2,400 semaglutide users and 1,500 tirzepatide users. The gap shrank:

What this means: women who use MHT may do slightly better on semaglutide, but these studies cannot rule out that MHT users differ in other ways, such as health, income or how closely they are followed. MHT is prescribed for menopausal symptoms, not for weight loss. Whether it suits you is a decision to make with a physician.

Should women over 50 worry about muscle and bone loss?

Evidence tier: 1–3 — FDA label data, a DXA sub-study, a randomised trial and a retrospective cohort.

This is where menopause and GLP-1s overlap most.

Lean mass. In a DXA sub-study of SURMOUNT-1 (73% women), about 75% of weight lost was fat and 25% was lean mass. That ratio held across most subgroups, including sex and age groups (adults over 65 among them), and was similar to the placebo group. The ratio is typical of dieting. The concern is that a woman in the transition is starting from a body that is already losing muscle.

Fractures. The Wegovy prescribing information reports that in the SELECT cardiovascular trial, more hip and pelvic fractures occurred in women on semaglutide than on placebo (1.0% vs 0.2%). The same pattern was seen in adults aged 75 and over.

Bone density. The data are thin but point the same way:

• In a Copenhagen trial, liraglutide alone reduced hip and spine density compared with exercise, while liraglutide plus exercise kept bone density stable.
• In a 2026 New York cohort (92% women, average age 64), hip bone loss was similar in users and matched non-users overall, but semaglutide or tirzepatide users without diabetes lost more hip bone than non-users (−1.0% vs −0.6% a year), and more weight loss meant more bone loss.
• A 2026 systematic review concluded the randomised evidence is too sparse to establish GLP-1 skeletal effects.

For women with osteopenia, osteoporosis or a past fracture, this is worth discussing with a physician before starting. Our guide on preventing muscle loss on GLP-1s covers resistance training and protein in detail, so we won't repeat it here.

Are side effects different for women?

Evidence tier: 1–3 — FDA label data for hair loss; older trial pools and cohort data for nausea.

Hair loss has the clearest label data. The Zepbound prescribing information reports hair loss in 7.1% of women versus 0.5% of men on tirzepatide. It was linked to weight reduction, and no one stopped the drug because of it. See does Ozempic cause hair loss?.

Nausea and vomiting appear more common in women, but the evidence is older and indirect. The current Wegovy and Zepbound labels do not break nausea down by sex. What we have:

• A pooled analysis of exenatide and liraglutide trials found that within every treatment group, more women than men reported gastrointestinal side effects.
• A Japanese cohort found that female sex was an independent risk factor for nausea and vomiting on GLP-1 drugs.

For scale, pooled STEP 1–3 data show nausea in 44% on semaglutide 2.4 mg versus 16% on placebo, mostly mild and during dose increases.

One more point for women in perimenopause: tirzepatide can make oral contraceptives less reliable after starting and after each dose increase. Our contraception guide explains the label advice.

What about peptides sold for "menopause belly"?

Evidence tier: 4 — animal studies and trials in other populations; no trials in menopausal women.

Three compounds come up again and again in menopause marketing. None has been studied in menopausal women.

Tesamorelin has the strongest data. In obese adults with low growth hormone, 12 months of tesamorelin cut visceral fat by about 35 cm² versus placebo without changing fat under the skin. But the Egrifta SV label states it is not indicated for weight loss and is weight-neutral. It raises IGF-1, and long-term heart safety is not established. In the EU, the company withdrew its application in 2012 after EMA regulators could not conclude the benefits outweighed the risks.

AOD-9604 reduced fat in obese mice. The company's human safety summary reported a placebo-like safety profile across six trials but published no weight-loss results.

5-amino-1MQ blocks an enzyme called NNMT. It reduced body weight and fat in diet-induced obese mice. There are no human trials of any kind.

Compared with approved GLP-1 drugs, which have trial data in thousands of women, these are not comparable options. Products sold online also carry purity and dosing risks; see our sourcing and safety guide.

Limitations of the evidence

Evidence tier: — summary of the evidence gaps above.

• The tirzepatide results by menopausal stage come from a post hoc, Lilly-funded analysis.
• The SURMOUNT sex analysis is an EASD 2024 conference abstract, reported only in a press release.
• The hormone-therapy findings are retrospective and observational; the larger study is a conference abstract, not yet peer-reviewed.
• Randomised bone data are too sparse to establish GLP-1 skeletal effects, and current labels do not break nausea down by sex.
• AOD-9604, 5-amino-1MQ and tesamorelin have no trials in menopausal women.

The bottom line

GLP-1 drugs produce large, well-documented weight loss in peri- and postmenopausal women, and women tend to lose more than men. The trade-off that matters after 50 is bone and muscle: about a quarter of lost weight is lean tissue, and the Wegovy label reports more hip and pelvic fractures in women on the drug (1.0% vs 0.2%). Hormone therapy may add a small benefit, but that evidence is observational. The "menopause belly" peptides have animal data or trials in other groups, not in menopausal women. Treatment choices belong in a conversation with a physician who knows your bone and heart history.

Related on this site

• Muscle loss on GLP-1s: how to prevent it
• Peptides for perimenopause and menopause
• GLP-1s, contraception and pregnancy planning
• GLP-1s in women: PCOS and fertility
• GLP-1 side effects and how they are managed
• Stopping a GLP-1: rebound and regain
• Peptides for women in 2026

References

• Greendale GA et al. Changes in body composition and weight during the menopause transition. JCI Insight 2019 — SWAN DXA data: fat gain doubles and lean mass falls from the start of the transition. PMID 30843880
• Lovejoy JC et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes 2008 — 4-year CT study; visceral fat rose only in women who became postmenopausal. PMID 18332882
• Janssen I et al. Testosterone and visceral fat in midlife women: the SWAN fat patterning study. Obesity 2010 — bioavailable testosterone predicted visceral fat more than estradiol. PMID 19696765
• Tchang BG et al. Body weight reduction in women treated with tirzepatide by reproductive stage. Obesity 2025 — post hoc SURMOUNT analysis by menopausal stage (Lilly-funded). PMID 40074721
• García LE et al. Tirzepatide associated with greater weight loss in women than men. EASD 2024 abstract — sex analysis of SURMOUNT 1–4; press release only. EurekAlert
• Verma S et al. Efficacy of semaglutide by sex in obesity-related HFpEF: STEP-HFpEF trials. J Am Coll Cardiol 2024 — greater weight loss in women; same symptom benefit. PMID 38913003
• Hurtado MD et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause 2024 — Mayo Clinic retrospective cohort, n=106. PMID 38446869
• Castaneda R et al. Menopause hormone therapy and weight loss response to GLP-1-based therapies in midlife women. The Menopause Society 2026 Annual Meeting abstract — matched cohort, not yet peer-reviewed. Patient Care report
• Look M et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab 2025 — DXA sub-study; ~25% of weight lost was lean mass. PMID 39996356
• Jensen SBK et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw Open 2024 — RCT; exercise protected bone during liraglutide weight loss. PMID 38916894
• Liu Y et al. Skeletal effect of semaglutide and tirzepatide in patients with increased risk of fractures. J Clin Endocrinol Metab 2026 — retrospective; more hip bone loss in users without diabetes. PMID 41655226
• Lai CH et al. Skeletal effects of GLP-1 receptor agonist therapy in adults with overweight or obesity: a systematic review. Arch Osteoporos 2026 — 8 RCTs; evidence insufficient. PMID 42920024
• Wharton S et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg. Diabetes Obes Metab 2022 — pooled STEP 1–3 GI side-effect rates. PMID 34514682
• Horowitz M et al. Upper and/or lower gastrointestinal adverse events with GLP-1 receptor agonists. Diabetes Obes Metab 2017 — more women than men reported GI side effects in every group. PMID 28058769
• Shiomi M et al. Clinical factors associated with nausea and vomiting in type 2 diabetes patients treated with GLP-1 receptor agonists. J Diabetes Investig 2019 — female sex an independent risk factor. PMID 30033675
• Makimura H et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion. J Clin Endocrinol Metab 2012 — tesamorelin RCT, n=60. PMID 23015655
• Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism in obese mice. Endocrinology 2001 — animal data. PMID 11713213
• Stier H et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. J Endocrinol Metab 2013 — company-funded safety summary of six trials. DOI 10.4021/jem157w
• Neelakantan H et al. Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice. Biochem Pharmacol 2018 — 5-amino-1MQ class, mouse data. PMID 29155147
• FDA. Wegovy (semaglutide) prescribing information — fracture data by sex from SELECT. DailyMed
• FDA. Zepbound (tirzepatide) prescribing information — hair loss by sex; oral contraceptive advice. DailyMed
• FDA. Egrifta SV (tesamorelin) prescribing information — HIV lipodystrophy only; not for weight loss. DailyMed
• EMA. Ferrer Internacional withdraws its marketing authorisation application for Egrifta (tesamorelin). 2012. EMA